for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Oxford BioMedica plc

OXB.L

Latest Trade

560.00GBp

Change

-8.00(-1.41%)

Volume

19,749

Today's Range

552.00

 - 

560.00

52 Week Range

461.50

 - 

794.88

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
568.00
Open
554.00
Volume
19,749
3M AVG Volume
1.97
Today's High
560.00
Today's Low
552.00
52 Week High
794.88
52 Week Low
461.50
Shares Out (MIL)
76.77
Market Cap (MIL)
436.11
Forward P/E
-68.64
Dividend (Yield %)
--

Next Event

Oxford BioMedica PLC Annual Shareholders Meeting

Latest Developments

More

Oxford BioMedica Posts H1 Revenue Down 9%

Oxford Biomedica Says Novo Holdings Agreed To Invest Up To £53.5 Mln In Group

Oxford Biomedica Says Japanese Approval Of Kymriah

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Oxford BioMedica plc

Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company's segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners. The R&D segment is engaged in the development of in-vivo and ex-vivo gene and cell therapy products, and the development of lentivirus-related platform technology. The Company provides a platform of technologies and capabilities with which it designs, develops and produces gene and cell-based medicines. The Company's product pipeline of OXB-102, OXB-201, OXB-202 and OXB-302 addresses neurodegenerative and ocular diseases, and a range of cancers. OXB-102 is indicated for Parkinson's disease. OXB-202 is indicated for Ocular (corneal graft rejection). OXB-302 is indicated for cancer disease. Its OXB-201 is indicated for wet age-related macular degeneration.

Industry

Biotechnology & Drugs

Contact Info

Windrush Court, Transport Way

+44.1865.783000

http://www.oxfordbiomedica.co.uk

Executive Leadership

Lorenzo Tallarigo

Non-Executive Chairman of the Board

John Dawson

Chief Executive Officer, Executive Director

Andrew John William Heath

Non-Executive Deputy Chairman of the Board, Senior Independent Director

Stuart Paynter

Chief Financial Officer, Director

Martin Diggle

Non-Executive Director

Key Stats

1.80 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, GBP)

2016

0.0K

2017

0.0K

2018

0.1K

2019(E)

0.1K
EPS (GBp)

2016

-30.000

2017

-14.500

2018

10.890

2019(E)

-8.275
Price To Earnings (TTM)
--
Price To Sales (TTM)
6.86
Price To Book (MRQ)
5.44
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
10.55
LT Debt To Equity (MRQ)
10.19
Return on Investment (TTM)
-9.41
Return on Equity (TTM)
-6.79

Latest News

Latest News

BRIEF-Oxford Biomedica Says Japanese Approval Of Kymriah

* NOTES AN ANNOUNCEMENT BY NOVARTIS THAT JAPAN'S MINISTRY OF HEALTH, LABOR AND WELFARE (MHLW) HAS APPROVED KYMRIAH Source text for Eikon: Further company coverage:

BRIEF-Oxford BioMedica Notes Longer-Term Analyses From Pivotal Kymriah Trials

* NOTES AN ANNOUNCEMENT BY NOVARTIS ON LONGER-TERM ANALYSES OF BOTH ELIANA AND JULIET PIVOTAL TRIALS

BRIEF-Oxford Biomedica Announces ‍Proposed Placing To Raise About 20.5 Mln STG

* OXFORD BIOMEDICA PLC - PROPOSED PLACING TO RAISE APPROXIMATELY £20.5 MILLION

Oxford BioMedica wins second $100 million gene therapy contract

Britain's Oxford BioMedica has won a second $100 million contract to supply gene therapy material, this time from Bioverativ, which agreed last month to be acquired by Sanofi for $11.6 billion.

BRIEF-Oxford Biomedica Says ‍Kymriah Receives Priority Review For Adult DLBCL​

* SAYS KYMRIAH RECEIVES PRIORITY REVIEW FOR ADULT DLBCL Source text for Eikon: Further company coverage:

BRIEF-Oxford Biomedica says Stuart Paynter joins group as CFO

* STUART PAYNTER TODAY JOINS GROUP AS CHIEF FINANCIAL OFFICER AND MEMBER OF BOARD OF DIRECTORS

Oxford BioMedica wins big contract for Novartis cell therapy

Novartis has signed a major contract with Oxford BioMedica that could earn the British company more than $100 million over three years for supplying the Swiss drugmaker with material for its novel cell therapy CTL019.

BRIEF-Oxford Biomedica completes new $55 million debt facility

* Completed a new $55 million debt facility with Oaktree Capital Management - Strategic Credit Strategy

BRIEF-Oxford Biomedica notes acceptance by FDA of a biologics license application filing for CTL019

* Oxford Biomedica notes acceptance by FDA of a biologics license application (BLA) filing for CTL019

BRIEF-Oxford biomedica says Trovax shown to induce beneficial anti-tumour immune responses

* Cyclophosphamide and Trovax independently shown to induce highly beneficial anti-tumour immune responses

BRIEF-Oxford Biomedica inks strategic alliance with Orchard Therapeutics

* Oxford Biomedica announces a strategic alliance with Orchard Therapeutics

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up